Evidence mapPaperPMID 41315571Full record

ArticleScientific reports2025

Examining the interplay between sdLDL, resistin, and BMI.

Fauzia Ashfaq, Mohammad Idreesh Khan, Abdulrahman A Alsayegh, Mohammed Bajahzer, Mohammed Abdullah Jeraiby, Fahad Saad Alhodieb, Fahmida Khatoon, Saleh Lafi Alshammari, Mirza Masroor Ali Beg

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Fauzia AshfaqDepartment of Clinical Nutrition, College of Nursing and Health Sciences, Jazan University, Jazan, 45142, Saudi Arabia.
Mohammad Idreesh KhanDepartment of Basic Health Sciences, College of Applied Medical Sciences, Qassim University, P.O. Box 6666, Buraydah, 51452, Saudi Arabia.
Abdulrahman A AlsayeghDepartment of Clinical Nutrition, College of Nursing and Health Sciences, Jazan University, Jazan, 45142, Saudi Arabia.
Mohammed BajahzerDepartment of Clinical Nutrition, College of Nursing and Health Sciences, Jazan University, Jazan, 45142, Saudi Arabia.
Mohammed Abdullah JeraibyDepartment of Basic Medical Science, College of Medicine, Jazan University, Jazan, 45142, Saudi Arabia.
Fahad Saad AlhodiebDepartment of Basic Health Sciences, College of Applied Medical Sciences, Qassim University, P.O. Box 6666, Buraydah, 51452, Saudi Arabia.
Fahmida KhatoonBiochemistry Department, College of Medicine, University of Hail, Hail, Saudi Arabia.
Saleh Lafi AlshammariPrince Sultan Cardiac Center & Health Services Directorate, P.O. Box 65434, Riyadh, Saudi Arabia.
Mirza Masroor Ali BegFaculty of Medicine, Alatoo International University, Bishkek, Kyrgyzstan. mirzamasroor1986@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Obesity is a major risk factor for many chronic diseases and is becoming a serious global health problem. Poor health outcomes are closely linked to body mass index (BMI). In obesity, changes in small dense low-density lipoprotein (sdLDL) may increase its ability to penetrate the endothelium, leading to atherosclerosis. Obesity also affects the metabolic and secretory functions of many tissues, which may raise serum resistin levels. This study included 300 participants with different BMI levels. We measured sdLDL and resistin in all participants. HbA1c was tested using whole blood in EDTA tubes. Serum from thawed samples was used to measure lipid parameters (triglycerides, cholesterol, HDL, LDL, VLDL, sdLDL) and resistin levels were analysed using ELISA. Obese participants had significantly higher HbA1c (p = 0.0004), LDL (p < 0.0001), triglycerides (p < 0.0001), cholesterol (p < 0.0001), and VLDL (p < 0.0001) compared to overweight and normal BMI groups, except for HDL, which was not significantly different. Smokers and participants with hypertension showed higher sdLDL (p = 0.03, p = 0.0001) and resistin levels (p = 0.03, p < 0.0001). Overweight participants had sdLDL levels of 21.95 mg/dl, while obese participants had 25.76 mg/dl, both significantly higher than the normal BMI group (p < 0.0001 for both). Resistin levels were also higher in overweight (1003 pg/mL) and obese participants (1355 pg/mL) compared to the normal BMI group (p < 0.0001 for p < 0.0001 ). SdLDL and resistin showed a positive correlation with each other and were significantly associated with BMI, systolic blood pressure, triglycerides, cholesterol, VLDL, and LDL, but negatively associated with HDL. ROC analysis indicated that sdLDL (cutoff: 18.55 mg/dl) and resistin (cutoff: 750 pg/mL) could serve as prognostic markers for overweight and obesity. Additionally, participants with normal BMI had resistin levels of 389.6 pg/mL, overweight participants had 300.6 pg/mL (p < 0.0001), and obese participants had 291.0 pg/mL (p < 0.0001). This study suggests that resistin and sdLDL levels are the primary cause of dyslipidemia and metabolic dysregulation in obesity. Both biomarkers are strong predictors of a higher BMI category, with resistin being a universal risk factor and sdLDL showing a male-specific correlation. Additionally, their high predictive accuracy confirms the usefulness of sdLDL and resistin as biomarkers for early risk assessment and shows how they can guide early intervention strategies for metabolic and cardiovascular risk linked to obesity.

Indexed as

Body Mass IndexLipoproteins, LDLObesityResistinAdultAgedBiomarkersFemaleGlycated HemoglobinHumansMaleMiddle AgedOverweightRisk FactorsTriglyceridesBiomarkersGlycated HemoglobinLipoproteins, LDLResistinRETN protein, humanTriglyceridesBody mass indexObesityPrognostic markerResistinSmall dense LDL

Identifiers

PMID41315571
PMCPMC12663111

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.